1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dental Membrane & Bone Graft Substitutes Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dental Membrane & Bone Graft Substitutes Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Technological Advancements
5.2. Emerging Trends In Dental Bone Graft
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Pandemic Impact on Industry
6. Global Dental Membrane & Bone Graft Substitutes Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017-2031
6.3.1. Dental Membrane
6.3.1.1. Resorbable
6.3.1.2. Non-resorbable
6.3.2. Dental Bone Graft
6.3.2.1. Autograft
6.3.2.2. Allograft
6.3.2.3. Demineralized Bone Matrix
6.3.2.4. Xenograft
6.3.2.5. Synthetic Bone Graft Substitute
6.4. Market Attractiveness Analysis, by Product
7. Global Dental Membrane & Bone Graft Substitutes Market Analysis and Forecast, by Material
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Material, 2017-2031
7.3.1. Hydrogel
7.3.2. Collagen
7.3.3. Polytetrafluoroethylene (PTFE)
7.3.4. Human Cells Sources
7.3.5. Hydroxyapatite (HA)
7.3.6. Tricalcium Phosphate (TCP)
7.3.7. Other Species
7.4. Market Attractiveness Analysis, by Material
8. Global Dental Membrane & Bone Graft Substitutes Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Hospitals
8.3.2. Dental Clinics
8.3.2.1. Individual Practice
8.3.2.2. Group Practice
8.3.3. Ambulatory Surgical Centers
8.4. Market Attractiveness Analysis, by End-user
9. Global Dental Membrane & Bone Graft Substitutes Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Dental Membrane & Bone Graft Substitutes Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017-2031
10.2.1. Dental Membrane
10.2.1.1. Resorbable
10.2.1.2. Non-resorbable
10.2.2. Dental Bone Graft
10.2.2.1. Autograft
10.2.2.2. Allograft
10.2.2.3. Demineralized Bone Matrix
10.2.2.4. Xenograft
10.2.2.5. Synthetic Bone Graft Substitute
10.3. Market Value Forecast, by Material, 2017-2031
10.3.1. Hydrogel
10.3.2. Collagen
10.3.3. Polytetrafluoroethylene (PTFE)
10.3.4. Human Cells Sources
10.3.5. Hydroxyapatite (HA)
10.3.6. Tricalcium Phosphate (TCP)
10.3.7. Other Species
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Hospitals
10.4.2. Dental Clinics
10.4.2.1. Individual Practice
10.4.2.2. Group Practice
10.4.3. Ambulatory Surgical Centers
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Material
10.6.3. By End-user
10.6.4. By Country
11. Europe Dental Membrane & Bone Graft Substitutes Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017-2031
11.2.1. Dental Membrane
11.2.1.1. Resorbable
11.2.1.2. Non-resorbable
11.2.2. Dental Bone Graft
11.2.2.1. Autograft
11.2.2.2. Allograft
11.2.2.3. Demineralized Bone Matrix
11.2.2.4. Xenograft
11.2.2.5. Synthetic Bone Graft Substitute
11.3. Market Value Forecast, by Material, 2017-2031
11.3.1. Hydrogel
11.3.2. Collagen
11.3.3. Polytetrafluoroethylene (PTFE)
11.3.4. Human Cells Sources
11.3.5. Hydroxyapatite (HA)
11.3.6. Tricalcium Phosphate (TCP)
11.3.7. Other Species
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Hospitals
11.4.2. Dental Clinics
11.4.2.1. Individual Practice
11.4.2.2. Group Practice
11.4.3. Ambulatory Surgical Centers
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Material
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Dental Membrane & Bone Graft Substitutes Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017-2031
12.2.1. Dental Membrane
12.2.1.1. Resorbable
12.2.1.2. Non-resorbable
12.2.2. Dental Bone Graft
12.2.2.1. Autograft
12.2.2.2. Allograft
12.2.2.3. Demineralized Bone Matrix
12.2.2.4. Xenograft
12.2.2.5. Synthetic Bone Graft Substitute
12.3. Market Value Forecast, by Material, 2017-2031
12.3.1. Hydrogel
12.3.2. Collagen
12.3.3. Polytetrafluoroethylene (PTFE)
12.3.4. Human Cells Sources
12.3.5. Hydroxyapatite (HA)
12.3.6. Tricalcium Phosphate (TCP)
12.3.7. Other Species
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Hospitals
12.4.2. Dental Clinics
12.4.2.1. Individual Practice
12.4.2.2. Group Practice
12.4.3. Ambulatory Surgical Centers
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Material
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Dental Membrane & Bone Graft Substitutes Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017-2031
13.2.1. Dental Membrane
13.2.1.1. Resorbable
13.2.1.2. Non-resorbable
13.2.2. Dental Bone Graft
13.2.2.1. Autograft
13.2.2.2. Allograft
13.2.2.3. Demineralized Bone Matrix
13.2.2.4. Xenograft
13.2.2.5. Synthetic Bone Graft Substitute
13.3. Market Value Forecast, by Material, 2017-2031
13.3.1. Hydrogel
13.3.2. Collagen
13.3.3. Polytetrafluoroethylene (PTFE)
13.3.4. Human Cells Sources
13.3.5. Hydroxyapatite (HA)
13.3.6. Tricalcium Phosphate (TCP)
13.3.7. Other Species
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Hospitals
13.4.2. Dental Clinics
13.4.2.1. Individual Practice
13.4.2.2. Group Practice
13.4.3. Ambulatory Surgical Centers
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Material
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Dental Membrane & Bone Graft Substitutes Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017-2031
14.2.1. Dental Membrane
14.2.1.1. Resorbable
14.2.1.2. Non-resorbable
14.2.2. Dental Bone Graft
14.2.2.1. Autograft
14.2.2.2. Allograft
14.2.2.3. Demineralized Bone Matrix
14.2.2.4. Xenograft
14.2.2.5. Synthetic Bone Graft Substitute
14.3. Market Value Forecast, by Material, 2017-2031
14.3.1. Hydrogel
14.3.2. Collagen
14.3.3. Polytetrafluoroethylene (PTFE)
14.3.4. Human Cells Sources
14.3.5. Hydroxyapatite (HA)
14.3.6. Tricalcium Phosphate (TCP)
14.3.7. Other Species
14.4. Market Value Forecast, by End-user, 2017-2031
14.4.1. Hospitals
14.4.2. Dental Clinics
14.4.2.1. Individual Practice
14.4.2.2. Group Practice
14.4.3. Ambulatory Surgical Centers
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Material
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. ACE Surgical Supply Co., Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Botiss Biomaterials GmbH
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Collagen Matrix, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. CURASAN AG
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Dentsply Sirona
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Geistlich Pharma
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. KLS Martin Group
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. LifeNet Health
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Medtronic plc
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. NovaBone Products LLC
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Osteogenics Biomedical
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. RTI Surgical Holdings, Inc.
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. Salvin Dental Specialties, Inc.
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
15.3.14. Straumann Group
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Product Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.14.5. Strategic Overview
15.3.15. Zimmer Biomet Holdings, Inc.
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Product Portfolio
15.3.15.3. Financial Overview
15.3.15.4. SWOT Analysis
15.3.15.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/